Online Webinar –Annual Aspen Conference —July 14, 2000
Below I’ve included a few slides and some notes; my notes may have errors of omission or transcription.
Can We Skip Liver Biopsies in Infants with Cholestasis? Jim Squires
- Data suggest that cholestasis in infants needs to be defined as direct bilirubin/conjugated bilirubin >0.3 (if TB <5) or 10% if TB >5.
- Identifying cholestasis is challenging as cholestasis occurs in ~1 in 2500 whereas jaundice occurs in 15% of all infants
- Genetic testing (eg. Cholestasis Panel, or exome) needs to be moved up earlier in diagnostic algorithm, after ultrasound completed and after A1AT & biliary atresia considered
Related blog posts:
- Blood test is better than liver biopsy for biliary atresia
- Will We Still Need a Liver Biopsy to Diagnose Biliary Atresia in a Few Years?
- Helpful Review on Biliary Atresia | gutsandgrowth
- Newborn bilirubin measurements for biliary atresia
- Neonatal cholestasis for neonatologists
Not part of webinar:
Pingback: Genetic Diagnostic Tools for Cholestasis | gutsandgrowth
Pingback: Aspen Webinar 2021 Part 8 -Neonatal Cholestasis | gutsandgrowth